A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis

• Status: Completed
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The overall objective of this trial is to evaluate the efficacy and safety of repeated Lamazym i.v. treatment, compared with placebo, in subjects 5-35 years of age with alpha-Mannosidosis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zymenex A/S
• Collaborator: European Commission

Criteria

Inclusion Criteria:

• Subject or subjects legally authorized guardian(s) must provide signed, informed consent prior to performing any trial-related activities

• The subject and his/her guardian(s) must have the ability to comply with the protocol

• The subject must have a confirmed diagnosis of alpha-Mannosidosis as defined by alpha-Mannosidase activity < 10% of normal activity (historical data)

• The subject must have an age at the time of screening ≥ 5 years and ≤ 35 years

• The subject must have the ability to physically and mentally cooperate in the tests

• The subject must have an ECHO without abnormalities that, in the opinion of the Investigator, would preclude participation in the trial

Exclusion Criteria:

• The subjects diagnosis cannot be confirmed by alpha-Mannosidase activity < 10% of normal activity

• The subject cannot walk without support

• Presence of known chromosomal abnormality and syndromes affecting psychomotor development, other than alpha-Mannosidosis

• History of BMT

• Presence of known clinically significant cardiovascular, hepatic, pulmonary, or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial

• Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial

• Pregnancy: Pregnant woman is excluded. Before start of the treatment the investigators will for women of childbearing potential perform a pregnancy test and decide whether or not there is a need for contraception

• Psychosis; any psychotic disease, also in remission, is an exclusion criteria

• Planned major surgery that, in the opinion of the Investigator, would preclude participation in the trial

• Participation in other interventional trials testing IMP (including Lamazym) within the last 3 months

• Adult patients who, in the opinion of the Investigator, would be unable to give consent, and who does not have any legal protection or guardianship

• Total IgE >800 IU/ml

• Known allergy to the IMP or any excipients (Sodium-Phosphate, Glycine, Mannitol)